LONA
insider transactionsLeonaBio, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-16.7K
0 buy · 16.7K sell
Net value · 365d
-$99.4K
$0 in · $99.4K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
10
0 buy · 16.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
56.0K sh
Own New
-
Grant·A
Director
$0
56.0K sh
Own New
-
Grant·A
Director
$0
56.0K sh
Own New
-
Grant·A
Robert Renninger KEY
CHIEF FINANCIAL OFFICER
$0
300.0K sh
Own New
-
Grant·A
GENERAL COUNSEL and CCO
$0
300.0K sh
Own New
-
Grant·A
CHIEF MEDICAL OFFICER
$0
350.0K sh
Own New
-
Grant·A
Director
$0
28.0K sh
Own New
-
Grant·A
Director
$0
28.0K sh
Own New
-
Grant·A
PRESIDENT and CEO
$0
750.0K sh
Own New
-
Grant·A
Director
$0
28.0K sh
Own New
-
Grant·A
Director
$0
28.0K sh
Own New
-
Grant·A
Director
$0
28.0K sh
Own New
-
Grant·A
CHIEF SCIENTIFIC OFFICER
$0
300.0K sh
Own New
-
Sell·S
Robert Renninger KEY
CHIEF FINANCIAL OFFICER
$4.9K
906 sh · $5.37
Own -5%
-
Sell·S
GENERAL COUNSEL and CCO
$7.1K
1.3K sh · $5.37
Own -7%
-
Sell·S
CHIEF MEDICAL OFFICER
$9.2K
1.7K sh · $5.37
Own -10%
-
Sell·S
PRESIDENT and CEO
$27.7K
5.2K sh · $5.37
Own -8%
-
Sell·S
CHIEF SCIENTIFIC OFFICER
$7.3K
1.4K sh · $5.37
Own -5%
-
Exercise·M
Robert Renninger KEY
CHIEF FINANCIAL OFFICER
$0
3.9K sh
Own New
-
Exercise·M
Robert Renninger KEY
CHIEF FINANCIAL OFFICER
$0
3.9K sh
Own +30%
-
Exercise·M
GENERAL COUNSEL and CCO
$0
5.7K sh
Own New
-
Exercise·M
GENERAL COUNSEL and CCO
$0
5.7K sh
Own +41%
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
7.4K sh
Own New
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
7.4K sh
Own +73%
-
Exercise·M
PRESIDENT and CEO
$0
22.3K sh
Own New
-
Exercise·M
PRESIDENT and CEO
$0
22.3K sh
Own +55%
-
Exercise·M
CHIEF SCIENTIFIC OFFICER
$0
5.9K sh
Own New
-
Exercise·M
CHIEF SCIENTIFIC OFFICER
$0
5.9K sh
Own +28%
-
Sell·S
Robert Renninger KEY
Chief Financial Officer
$2.0K
297 sh · $6.88
Own -2%
-
Sell·S
General Counsel and CCO
$6.0K
876 sh · $6.88
Own -6%
-
Sell·S
CHIEF SCIENTIFIC OFFICER
$6.0K
876 sh · $6.88
Own -4%
-
Sell·S
CHIEF MEDICAL OFFICER
$11.3K
1.6K sh · $6.88
Own -14%
-
Sell·S
President and CEO
$17.8K
2.6K sh · $6.88
Own -6%
-
Exercise·M
Robert Renninger KEY
Chief Financial Officer
$0
1.2K sh
Own New
-
Exercise·M
Robert Renninger KEY
Chief Financial Officer
$0
1.2K sh
Own +10%
-
Exercise·M
General Counsel and CCO
$0
3.7K sh
Own New
-
Exercise·M
General Counsel and CCO
$0
3.7K sh
Own +33%
-
Exercise·M
CHIEF SCIENTIFIC OFFICER
$0
3.7K sh
Own New
-
Exercise·M
CHIEF SCIENTIFIC OFFICER
$0
3.7K sh
Own +20%
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
4.7K sh
Own New
-
Exercise·M
CHIEF MEDICAL OFFICER
$0
4.7K sh
Own +65%
-
Exercise·M
President and CEO
$0
10.8K sh
Own New
-
Exercise·M
President and CEO
$0
10.8K sh
Own +33%
-
Grant·A
Robert Renninger KEY
Chief Financial Officer
$2.3K
1.0K sh · $2.31
Own +9%
-
Grant·A
CHIEF SCIENTIFIC OFFICER
$2.3K
1.0K sh · $2.31
Own +6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 5, 2026 | Peter B. Silverman | Grant A | 56.0K | $0 |
| May 5, 2026 | Natalie C. Holles | Grant A | 56.0K | $0 |
| May 5, 2026 | Fred Callori | Grant A | 56.0K | $0 |
| Apr 9, 2026 | Robert Renninger KEY | Grant A | 300.0K | $0 |
| Apr 9, 2026 | Mark Worthington | Grant A | 300.0K | $0 |
| Apr 9, 2026 | Javier San Martin | Grant A | 350.0K | $0 |
| Apr 9, 2026 | Kelly A Romano | Grant A | 28.0K | $0 |
| Apr 9, 2026 | Michael A. Panzara | Grant A | 28.0K | $0 |
| Apr 9, 2026 | Mark James Litton KEY | Grant A | 750.0K | $0 |
| Apr 9, 2026 | Grant Pickering | Grant A | 28.0K | $0 |
| Apr 9, 2026 | James A Johnson | Grant A | 28.0K | $0 |
| Apr 9, 2026 | John M Fluke JR | Grant A | 28.0K | $0 |
| Apr 9, 2026 | Kevin Church | Grant A | 300.0K | $0 |
| Mar 4, 2026 | Robert Renninger KEY | Sell S | 906 | $4.9K |
| Mar 4, 2026 | Mark Worthington | Sell S | 1.3K | $7.1K |
| Mar 4, 2026 | Javier San Martin | Sell S | 1.7K | $9.2K |
| Mar 4, 2026 | Mark James Litton KEY | Sell S | 5.2K | $27.7K |
| Mar 4, 2026 | Kevin Church | Sell S | 1.4K | $7.3K |
| Mar 3, 2026 | Robert Renninger KEY | Exercise M | 3.9K | $0 |
| Mar 3, 2026 | Robert Renninger KEY | Exercise M | 3.9K | $0 |
| Mar 3, 2026 | Mark Worthington | Exercise M | 5.7K | $0 |
| Mar 3, 2026 | Mark Worthington | Exercise M | 5.7K | $0 |
| Mar 3, 2026 | Javier San Martin | Exercise M | 7.4K | $0 |
| Mar 3, 2026 | Javier San Martin | Exercise M | 7.4K | $0 |
| Mar 3, 2026 | Mark James Litton KEY | Exercise M | 22.3K | $0 |
| Mar 3, 2026 | Mark James Litton KEY | Exercise M | 22.3K | $0 |
| Mar 3, 2026 | Kevin Church | Exercise M | 5.9K | $0 |
| Mar 3, 2026 | Kevin Church | Exercise M | 5.9K | $0 |
| Jan 2, 2026 | Robert Renninger KEY | Sell S | 297 | $2.0K |
| Jan 2, 2026 | Mark Worthington | Sell S | 876 | $6.0K |
| Jan 2, 2026 | Kevin Church | Sell S | 876 | $6.0K |
| Jan 2, 2026 | Javier San Martin | Sell S | 1.6K | $11.3K |
| Jan 2, 2026 | Mark James Litton KEY | Sell S | 2.6K | $17.8K |
| Dec 31, 2025 | Robert Renninger KEY | Exercise M | 1.2K | $0 |
| Dec 31, 2025 | Robert Renninger KEY | Exercise M | 1.2K | $0 |
| Dec 31, 2025 | Mark Worthington | Exercise M | 3.7K | $0 |
| Dec 31, 2025 | Mark Worthington | Exercise M | 3.7K | $0 |
| Dec 31, 2025 | Kevin Church | Exercise M | 3.7K | $0 |
| Dec 31, 2025 | Kevin Church | Exercise M | 3.7K | $0 |
| Dec 31, 2025 | Javier San Martin | Exercise M | 4.7K | $0 |
| Dec 31, 2025 | Javier San Martin | Exercise M | 4.7K | $0 |
| Dec 31, 2025 | Mark James Litton KEY | Exercise M | 10.8K | $0 |
| Dec 31, 2025 | Mark James Litton KEY | Exercise M | 10.8K | $0 |
| Nov 18, 2025 | Robert Renninger KEY | Grant A | 1.0K | $2.3K |
| Nov 18, 2025 | Kevin Church | Grant A | 1.0K | $2.3K |
About LONA insider trading
This page tracks insider transactions for LeonaBio, Inc. (LONA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.